<DOC>
	<DOCNO>NCT00417391</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy pharmacokinetics profile 1 4 mg/kg/day RR110 administrate orally 8 week patient active Crohn 's disease .</brief_summary>
	<brief_title>Phase II Study RR110 Patients With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Patients CDAI score range 220 450 Patients CRP &gt; 1 mg/dL Patients hospitalize least 2 week first administration Patients previously use antiTNF antibody , cyclosporine , methotrexate tacrolimus within 12 week screen Patients surgical bowel resection within 4 week screen Patients previously use total parental nutrition 900 kcal/day enteral nutrition within 4 week screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>